Markets Maxim resumes coverage of Moleculin Biotech at buy; PT $3 Maxim Group resumed coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.11 on June 5. On May 1, the SEC suspended trading in Moleculin, citing questions about the... June 8, 2020